$10m boost for Calypte HIV urine test launch
This article was originally published in Clinica
Calypte Biomedical has raised more than $10 million in a private placement which will enable the firm to proceed with the manufacture of its urine-based test for HIV-1. It will also use the money to undertake clinical trials for a home collection version of the test.
You may also be interested in...
Health technology assessment body says that while iRhythm Technologies’ Zio XT service improves cardiac arrhythmia detection, more data must be collected to address evidence gaps about its benefit.
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.